US 10,239,883 B2 · 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors

Abstract

The present invention relates to 6-5 membered fused pyridine ring compounds according to Formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to Formula (I) in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

Claims14

Dependent claims

A method of treating chronic lymphocytic leukemia in a human subject, the method comprising administering to the human subject a compound that is

(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide, having the structure:
or a pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.

Facts

Application

15/668,385Filed 3 Aug 2017 · continuation

Priority

EP 1117457819 Jul 2011

Published

US 2018/0179212 A128 Jun 2018

Granted

26 Mar 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification45 codes

C07D 487/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A61K 31/4985
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: pyrazines or piperazines…
A61K 31/501
Pyridazines; Hydrogenated pyridazines: not condensed and containing further heterocyclic rings
A61K 31/506
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: not condensed and containing further heterocyclic rings

Family

Application61/509,397Us provisional application · filed 19 Jul 2011

PCT/EP2012/063552Parent of this division · filed 11 Jul 2012

Application15/019,543Parent of this continuation · filed 9 Feb 2016

US 2018/0179212 A1Pre-grant publication · published 28 Jun 2018

US 9,758,524 B2Parent of this continuation

Application14/233,418Parent of this division

US 9,290,504 B2Parent of this division

Application15/019,543Parent of this division

US 2014/0155385 A1Published application

US 2016/0151364 A1Published application

US 10,239,883 B2This patent

From the US filing history. Foreign family members aren’t listed.

4-imidazopyridazin-1-yl-benzamides as BTK inhibitors

Life of this patent

4-imidazopyridazin-1-yl-benzamides as BTK inhibitors

Life of this patent

Abstract

Claims14